Research progress on the mechanism of role of podoplanin in sepsis / 中华危重病急救医学

Podoplanin (PDPN) is a small transmembrane mucin-like glycoprotein which is expressed on the surface of lymphatic endothelial cells, glomerular podocytes, type-Ⅰ alveolar epithelial cells and some tumor cells. PDPN plays crucial function in variety of physiological and pathological processes such as embryonic development, immunoreaction, inflammation and cancer. C-type lectin-like receptor 2 (CLEC2) is mainly expressed on the platelet which specific ligand is PDPN. The interaction between PDPN and CLEC2 has received extensive attention. In this review, we summarized recent researches on the role of in sepsis and elaborated the possible mechanisms and some potential therapies for sepsis by targeting PDPN, which may provide theoretical basis for the mechanism and treatment of sepsis.

Study on the correlation of CLEC-2 with the severity of acute cerebral infarction and cerebral artery stenosis / 中风与神经疾病杂志

@#Objective　To explore the relationship between C-type lectin-like receptor 2 (CLEC-2) on platelet surface and the severity of acute cerebral infarction and cerebral artery stenosis.Methods　Prospectively selected 211 patients with acute cerebral infarction who were hospitalized for the first time as the infarction group,the patients were grouped according to the NIHSS score and cranial MRA examination results on admission,and 105 healthy patients were collected as the control group.Venous blood of all patients was collected for CLEC-2 detection on the day of admission,and the level of CLEC-2 between each group was analyzed.Results　The level of plasma CLEC-2 in the infarction group was significantly higher than that in the control group (P＜0.001).The level of CLEC-2 in the mild,moderate and severe acute cerebral infarction subgroups gradually increased,and the difference between the two groups was statistically significant (P＜0.001).After adjusting for confounding factors,the concentration of CLEC-2 (OR=1.034,95%CI 1.020~1.048,P<0.001) was an independent risk factor for cerebral artery stenosis in patients with acute cerebral infarction.Receiver operating characteristic (ROC) curve analysis showed that the area under the curve for CLEC-2 to predict cerebral artery stenosis was 0.862 (95%CI 0.812~0.912,P<0.001);the best cut-off value was 266.40pg/ml,predicted the sensitivity of cerebral artery stenosis was 80.3%,and the specificity was 80.9%.Conclusion　Elevated levels of CLEC-2 can assess the severity of ACI patients,is an independent risk factor for cerebral artery stenosis,and has certain value in predicting cerebral artery stenosis.

Recent advance in role of C-type lectin-like receptor 2 in acute ischemic stroke / 中华神经医学杂志

Acute ischemic stroke (AIS) is one of the main causes of death and disability in adults, which has brought a heavy burden to society and families. The intertwined process of thrombosis and thrombus inflammation plays a key role in the pathogenesis of AIS. The latest studies find that C-type lectin-like receptor 2 (CLEC-2) may play an important role in cerebral ischemia/reperfusion injury in mice by promoting thrombus inflammation, and its level is related to the progression of AIS and prognoses of patients with AIS. The author reviews the physiological and pathological effects of CLEC-2 and its related research progress in AIS, with a view to provide new research evidences for the occurrence and development of AIS and related treatments.

Progress in platelet-activating C-type lectin-like receptor-2 and hematogenous metastasis of tumor / 肿瘤

The process of tumor metastasis is extremely complicated. The growing evidence indicates that platelets are closely involved in hematogenous metastasis of tumors. Platelets can secret an array of bioactive factors to help cancer cells evading immune surveillance and natural killer cell-mediated cytotoxicity, induce epithelialmesenchymal transition (EMT), proliferation, invasion of tumor cells, and subsequently promote cancer progression. Recent studies have showed that the interaction between platelet-activating C-type lectin-like receptor-2 (CLEC-2) and its ligand podoplanin (PDPN) can activate platelets and affect the proliferation, migration, and metastasis of tumor cells. Therefore, using anti-CLEC-2 antibody and blocking the CLEC-2/PDPN interaction maybe the novel anticancer treatments. This review illuminates the role of CLEC-2 in hematogenous metastasis of tumors and its clinical application prospect.